CD34 and ischemic cardiomyopathy: Vrtovec’s study utilizing transendocardial injection of CD34+ cells for the treatment of ischemic cardiomyopathy achieved an 8% improvement of LVEF (p < 0.001) and similar improvements in non-ischemic dilated cardiomyopathy [21].